Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$890.68 USD
-15.86 (-1.75%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $886.00 -4.68 (-0.53%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Price, Consensus and EPS Surprise
REGN 890.68 -15.86(-1.75%)
Will REGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REGN
EXEL vs. REGN: Which Stock Is the Better Value Option?
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Regeneron (REGN) Reports Next Week: What You Should Expect
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
Other News for REGN
AbbVie reports positive results from Rinvoq versus Dupixent study
Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
Regeneron, Mammoth collaborate to purse next-generation gene editing
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)